Transaction DateRecipientSharesTypePriceValue
3rd November 2020Andrew A. F. Hack5,365,659Conversion of derivative$0.00
3rd November 2020Andrew A. F. Hack250,000Open or private purchase$24.00$6,000,000.00
26th October 2020Andrew A. F. Hack487,500Grant/award etc.$10.00$4,875,000.00
17th July 2020Robert Janssen50,000Open or private sale$11.09$554,500.00
27th May 2020Andrew A. F. Hack1,000,000Open or private purchase$5.00$5,000,000.00
19th May 2020Robert Janssen15,000Open or private sale$6.33$94,950.00
6th May 2020Robert Janssen28,000Open or private sale$4.52$126,560.00
5th May 2020Robert Janssen9,000Open or private sale$4.43$39,870.00
7th April 2020Andrew A. F. Hack2,800,000Open or private purchase$5.59$15,652,000.00
7th April 2020Andrew A. F. Hack645,667Open or private purchase$7.74$4,997,462.58
Dynavax Technologies
Dynavax Technologies logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 5/10.

Dynavax Technologies Corp. is a biopharmaceutical company. It focuses on leveraging the body's innate and adaptive immune responses through toll-like receptor stimulation. The company was founded by Lawrence M. Lichtenstein, Dennis A. Carson, and Eyal Raz on August 29, 1996.

Ticker: DVAX
Sector: Health Technology
Industry: Biotechnology
SEC Central Index Key (CIK): 1029142
Employees: 231
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Cash at Carrying Value: $60 M (0%)
Inventory, Net: $54 M (0%)
Assets, Current: $265 M (27%)
Property, Plant and Equipment, Net: $30 M (-4%)
Other Assets, Noncurrent: $3 M (-4%)
Assets: $329 M (18%)
Accounts Payable, Current: $3 M (-70%)
Accrued Liabilities, Current: $13 M (-10%)
Liabilities, Current: $53 M (0%)
Long-term Debt, Excluding Current Maturities: $180 M (0%)
Other Liabilities, Noncurrent: $2 M (48%)
Liabilities: $271 M (0%)
Common Stock, Value, Issued: $109 Th (29%)
Common Stock, Shares, Issued: $110 Th (30%)
Additional Paid in Capital, Common Stock: $1 B (9%)
Retained Earnings (Accumulated Deficit): $1 B (5%)
Accumulated Other Comprehensive Income (Loss), Net of Tax: $2 M (-12%)
Stockholders' Equity (Parent): $58 M (0%)
Liabilities and Equity: $329 M (18%)
Revenue: $3 M (-80%)
Research and Development: $6 M (-44%)
Restructuring Charges: $9 M (0%)
Operating Income/Loss: $23 M (-45%)